"Enhanced Antitumour Effect of Liposomal Daunorubicin Using Antibody-Phospholipase C Conjugates or Fusion Protein."

According to the authors' abstract of an article published in International Journal of Oncology, "We have developed a new two-step method for targeting cytotoxic drugs to tumour cells. The method firstly involves the binding to tumour cells of antibody-phospholipase C immunoconjugates or fusion proteins. [After] washing or clearance of the immunoconjugates, liposomes were introduced which are specifically lysed at the tumour site by PLC to release their cytotoxic contents in the vicinity of the tumour cells. For two alternative human cell lines, a synergistic inhibition of cell proliferation was seen for combined treatment with a specific immunoconjugate and daunorubicin encapsulated...

Want to see the full article?

• Purchase this article for only $3.00